Biomarker - Panitumumab Response With KRAS Wild Type MCC
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is an exploratory study in which all eligible subjects are given Panitumumab according
to the dose and schedule approved by Health Canada. The purpose of this research study is to
determine whether the presence of certain biomarkers (substances measurable in blood, normal
cells or tumour tissue) are associated with an increased or decreased chance of benefit from
panitumumab.